HALO - Halozyme Therapeutics - Stock & Dividends

Halozyme Therapeutics Inc. is a biopharma technology platform company that develops and commercializes innovative enzymes and devices to improve the delivery of injectable biologics and other therapeutic molecules. The company's proprietary technology is based on a patented recombinant human hyaluronidase enzyme (rHuPH20), which enables the delivery of a wide range of medications, including monoclonal antibodies, small molecules, and fluids, through subcutaneous injection.

The company's product portfolio includes Hylenex recombinant, which facilitates subcutaneous fluid administration for hydration and enhances the dispersion and absorption of other injected drugs. Additionally, Halozyme offers a range of medications for various indications, including HIV, multiple sclerosis, testosterone replacement therapy, and cancer treatment. These products include rilpivirine, cabotegravir, and N6LS BNAB for HIV treatment, ocrelizumab for multiple sclerosis, and XYOSTED for testosterone replacement therapy.

Halozyme also provides several medications for cancer treatment, including Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo for breast cancer, as well as Mabthera SC for chronic lymphocytic leukemia. Furthermore, the company offers HYQVIA for primary immunodeficiency disorders and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma.

In addition to its proprietary products, Halozyme also partners with other pharmaceutical companies to develop and commercialize new medications. The company's pipeline includes several promising candidates, such as Epinephrine Injection for allergic reactions, nivolumab+relatlimab and ANTI-TIM3 for solid tumors, and ARGX-117 for multifocal motor neuropathy.

Halozyme Therapeutics Inc. was founded in 1998 and is headquartered in San Diego, California. With a strong focus on innovation and collaboration, the company is committed to improving patient outcomes and advancing the field of biopharma technology.